One of the most remarkable aspects of Niche Science & Technology Ltd. is their commitment to staying at the forefront of advancements in science and technology. The team is known for its professionalism and reliability. They exhibit exceptional communication skills, ensuring that projects progress smoothly and efficiently. Many EVERSANA colleagues have worked with the Niche team in the following areas and have always reported outstanding results:
"Having had the privilege of interacting with Niche Science & Technology Ltd. on various projects, I can attest to their unparalleled dedication to excellence, innovation and integrity."
Niche began work with EVERSANA in 2022, providing support guiding a late-stage development biotech company with an asset for Alzheimer’s disease. The company had expended considerable resources on delivery of their Phase II/III clinical programme. Their latest Phase III trial had followed a 15-month study in mild to moderate patients that showed no treatment benefits. Their latest trial was also apparently negative, possibly as a result of poor study design and the company was trying to make sense of their data. The Niche team devised regulatory strategy around interpretation of the opinion offered by the FDA and MHRA and future study designs. They also provided advice on the use of publicly available registry data to compare against their own data.
Niche partnered with Erytech Pharma to rescue and rewrite substandard clinical study reports, delivering a high-quality.
read moreNiche provided DemeRx with end-to-end support to launch a pioneering ibogaine addiction trial, covering site.
read moreNiche played a foundational role in securing EMA approval for Strimvelis, the world's first ex vivo autologous gene.
read moreThe clinical evidence Niche helped generate for Funxional's novel anti-inflammatory compound FX125L proved compelling.
read moreNiche prepared the full regulatory package for HOOKIPA's groundbreaking arenavirus immunotherapy platform, enabling the.
read moreWhat began as a CSR writing request grew into a broad regulatory partnership, with Niche guiding iOnctura's roginolisib.
read moreRegulatory documentation, ILAP designation and a robust clinical protocol for the Sunlight Trial — Niche helped.
read moreWorking from poor quality hard copy source materials, Niche rescued and rebuilt Thromboserin's Investigator's Brochure.
read moreFrom Phase I protocols to a full Marketing Authorisation Application, Niche was VectivBio's embedded regulatory writing.
read moreGet our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
